| abstract |
IT REFERS TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES: 1) A FIRST SELECTED COMPONENT OF FLUOXETINE, VENLAFAXINE, MILNACIPRAN AND DULOXETINE (N-METHYL-3- (1-NAFTALENYLOXI) -3- (2-THENYL) PROPANAMINE); WHICH RAISES THE AVAILABILITY OF SEROTONINE, NOREPINEFRINE AND DOPAMINE IN THE BRAIN BY INHIBITING ITS REABSORPTION; IN COMBINATION WITH 2) A SECOND COMPONENT SUCH AS ALPRENOLOL, WAY 100135; N- (T-BUTIL) -3- [4- (2-METOXIFENIL) PIPERAZINA-1-IL] -2-FENILPROPANAMIDA, ESPIPERONA, PINDOLOL, (S) -UH-301; (S) -5-FLUOR-8-HIDROXI-2-DIPROPILAMINO-TETRALINA, PENBUTOLOL, PROPRANOLOL, TERTATOLOL AND A COMPOUND OF FORMULA I WHERE OF PREFERENCE Ar IS INDOLIL, Z IS CICLOALQUILO C4-C8; RENT C2-C10 OPTIONALLY REPLACED WITH PHENYL; THAT THE ACTION OF THE FIRST COMPONENT IS ANTAGONIST OF THE SEROTONIN RECEPTOR AND POWER; MAY SUCH COMPOSITION BE USEFUL IN THE TREATMENT OF DEPRESSION, OBSESSIVE COMPULSIVE DISEASE, OBESITY, URINARY INCONTINENCE |